Education
About Us
Working with TipRanks
Follow Us
Aldeyra Therapeutics (ALDX)
NASDAQ:ALDX
ALDX Stock Chart & Stats
$4.18
-$0.07(-1.37%)
At close: 4:00 PM EST
$4.18
-$0.07(-1.37%)
Day’s Range― - ―
52-Week Range$1.14 - $7.20
Previous CloseN/A
Volume102.94K
Average Volume (3M)1.27M
Market Cap
$250.28M
Enterprise ValueN/A
Total Cash (Recent Filing)$75.30M
Total Debt (Recent Filing)$15.54M
Price to Earnings (P/E)―
Beta2.35
Next Earnings
Apr 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding60,162,773
10 Day Avg. Volume632,116
30 Day Avg. Volume1,271,353
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)4.18
Price to Sales (P/S)0.00
P/FCF Ratio-6.87
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$9.50Price Target Upside127.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.13
Revenue Forecast (FY)$39.98M
Bulls Say, Bears Say
Bulls Say
Regulatory ProgressFDA acceptance of ALDX's resubmitted NDA for Reproxalap in dry eye disease marks a key milestone following prior CRLs, with PDUFA of Dec 16th.
Strategic PartnershipsThere is an outstanding option agreement with AbbVie for the potential co-exclusive license to develop, manufacture, and commercialize Reproxalap in the US market, including significant milestone payments.
Therapeutic DifferentiationReproxalap can offer patients a differentiated efficacy profile in dry eye, underscoring acute and chronic activity for reducing dry eye symptoms with ocular discomfort, as well as acute activity for reducing ocular redness.
Bears Say
Clinical Trial ChallengesThe completed DED field trial did not meet the primary endpoint of improvement in dry eye symptoms relative to vehicle control.
Financial ConcernsThe cash position could become limiting as Aldeyra shifts to exploring systemic applications of RASP scavenging.
Regulatory DelayThe PDUFA target action date for Reproxalap has been extended from December 16, 2025, to March 16, 2026.
Aldeyra Therapeutics News
ALDX FAQ
What was Aldeyra Therapeutics’s price range in the past 12 months?
Aldeyra Therapeutics lowest stock price was $1.14 and its highest was $7.20 in the past 12 months.
What is Aldeyra Therapeutics’s market cap?
Aldeyra Therapeutics’s market cap is $250.28M.
When is Aldeyra Therapeutics’s upcoming earnings report date?
Aldeyra Therapeutics’s upcoming earnings report date is Apr 30, 2026 which is in 111 days.
How were Aldeyra Therapeutics’s earnings last quarter?
Currently, no data Available
Is Aldeyra Therapeutics overvalued?
According to Wall Street analysts Aldeyra Therapeutics’s price is currently Undervalued.
Does Aldeyra Therapeutics pay dividends?
Aldeyra Therapeutics does not currently pay dividends.
What is Aldeyra Therapeutics’s EPS estimate?
Aldeyra Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aldeyra Therapeutics have?
Aldeyra Therapeutics has 60,162,773 shares outstanding.
What happened to Aldeyra Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aldeyra Therapeutics?
Currently, no hedge funds are holding shares in ALDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aldeyra Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.50 (127.27% Upside)
$9.50 (127.27% Upside)
Blogger Sentiment
Bullish
ALDX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 3.8%
Last 30 Days ▲ 3.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-18.19%
12-Months-Change
Fundamentals
Return on Equity
-64.31%
Trailing 12-Months
Asset Growth
-33.68%
Trailing 12-Months
Company Description
Aldeyra Therapeutics
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
ALDX Stock 12 Month Forecast
Average Price Target
$9.50
▲(127.27% Upside)
Technical Analysis
Omeros
―
Galectin Therapeutics
―
Foghorn Therapeutics
―
Candel Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
12.93% Insiders
8.77% Mutual Funds
29.54% Other Institutional Investors
39.61% Public Companies and
Individual Investors